Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc News Story

$9.56 0.2  2.2%

Last Trade - 30/07/21

Sector
Healthcare
Size
Small Cap
Market Cap £242.2m
Enterprise Value £34.4m
Revenue £n/a
Position in Universe 4135th / 7015

BRIEF-Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, And Preliminary Efficacy Data Of Bdtx-189 In Advanced Solid Tumors Harboring Egfr Or Her2 Alterations

Wed 19th May, 2021 10:14pm
May 19 (Reuters) - Black Diamond Therapeutics Inc  BDTX.O :
    * BLACK DIAMOND THERAPEUTICS PRESENTS PHASE 1
PHARMACOKINETIC,
SAFETY, AND PRELIMINARY EFFICACY DATA OF BDTX-189 IN ADVANCED
SOLID TUMORS HARBORING EGFR OR HER2 ALTERATIONS

Source text for Eikon:  ID:nGNX9gnWMV 
Further company coverage:  BDTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.